Bladder Cancer | Tumor

CURE’s bladder cancer page is a go-to resource for oncology news and updates in the world of bladder cancer. Here, readers will find cancer articles, videos, podcasts, and more with expert insight into the latest treatments and research in bladder cancer.

New Test May Identify Those Unlikely to Respond to Popular Bladder Cancer Treatment

August 30th 2018

While there is currently no definitive way to predict who will respond and who will not, researchers at Brighton and Sussex Medical School in the United Kingdom are working on a blood test that could identify about half of those who may not.

A Deeper Look Into a 40-Year-Old Bladder Cancer Treatment: Bacillus Calmette-Guerin

August 23rd 2018

CURE spoke with Matthew Mossanen, M.D., from the Division of Urology at Brigham and Women’s Hospital, about what Bacillus Calmette-Guérin (BCG) is and what patients should know about this treatment option.

Immunotherapy in Bladder Cancer: FDA Updates Labels, Approves Diagnostic Tools

August 17th 2018

The Food and Drug Administration (FDA) updated the prescribing information for two immunotherapy agents – Keytruda (pembrolizumab) and Tecentriq (atezolizumab) – approved to treat patients with locally advanced or metastatic bladder cancer who are not eligible for cisplatin-based therapy.

Two Large Trials Investigate Combination Immunotherapy in Bladder Cancer

July 31st 2018

With five immunotherapy drugs approved in the bladder cancer space, the next question researchers find themselves asking is whether these drugs would work better alone or as part of a combination for patients with metastatic disease.

When Cancer Clusters, Create a Medical Family Tree

July 28th 2018

Creating a medical family tree is helpful. If cancer is common, noting which branches include it can help inform decisions.

Gender Influences Bladder Cancer Survival

July 23rd 2018

Women are more likely to die from bladder cancer earlier on after diagnosis, according to recent study findings published in the European Journal of Cancer. However, after that time frame the risk of death is higher for men.

Pre-Surgical Bladder Cancer Treatment: What's Next

July 16th 2018

Many questions still remain in the treatment of localized bladder cancer, like which patients are best suited to receive neoadjuvant (pre-surgery) chemotherapy – a procedure that could be beneficial to many, but comes with increased toxicity.

Gender May Play a Role in Immunotherapy Efficacy, Further Studies Are Warranted

June 29th 2018

Because little is known about the effect of patients' sex on the efficacy of immune checkpoint inhibitors as cancer treatments, the researchers performed a systematic review and meta-analysis to determine the heterogeneity of immune checkpoint inhibitor efficacy between men and women.

Expert Talks Immunotherapy, Unanswered Questions in Metastatic Bladder Cancer

June 22nd 2018

Immunotherapy is being tested in the second-line setting for metastatic bladder cancer. Pending trial results, the role of chemotherapy for this patient population may change.

Erdafitinib Shows Promise in Advanced FGFR-Positive Bladder Cancer

June 21st 2018

Phase 2 study results showed that patients with metastatic or unresectable, FGFR-positive bladder cancer may have a third-line option for treatment.

FDA Updates Immunotherapy Labels for Bladder Cancer Treatment

June 21st 2018

The FDA has incorporated PD-L1 status into the labels for Keytruda (pembrolizumab) and Tecentriq (atezolizumab) for existing frontline approvals for platinum-ineligible patients with urothelial carcinoma, based on lower overall survival (OS) rates with the PD-1/PD-L1 inhibitors compared with platinum-based chemotherapy for patients with PD-L1–low expressing platinum-eligible urothelial carcinoma.

Contagious Enthusiasm

June 20th 2018

Oncolytic, or engineered, viruses that infect and kill cancer cells are showing promise.

Investigational Drug Shows Promise in Patients with Metastatic Urothelial Cancer

June 5th 2018

Enfortumab vedotin may be a potential novel therapy for patients with locally advanced or metastatic urothelial cancer, according to updated phase 1 study findings presented during the 2018 American Society of Clinical Oncology (ASCO) Annual Meeting.

Monitoring Immunotherapy's Side Effects in Genitourinary Cancers

May 24th 2018

PD-1 and PD-L1 inhibitors are generally well-tolerated, so most patients face little or no issues with the drugs. However, there are still some things to look out for.

Examining Stress and Quality of Life in Bladder Cancer

May 21st 2018

Patients with non-muscle invasive bladder cancer experience high levels of distress, according to one study.

Immunotherapy in GU Cancers: Combinations Are the Next Step

May 4th 2018

Immunotherapy is making landmark change in the treatment of patients with genitourinary (GU) cancers, with bladder cancer being the pioneer in the field, having five FDA-approved checkpoint inhibitors. But kidney cancer is not far behind, with a breakthrough therapy designation granted for a Keytruda (pembrolizumab) combination this past January.

Combination Improves Responses, Misses Survival Endpoint in Bladder Cancer Trial

April 25th 2018

The combination use of Cyramza (ramucirumab) plus docetaxel showed improvements in objective response rate (ORR) and a positive trend in overall survival (OS) among patients with advanced bladder cancer, according to additional results from the phase 3 RANGE trial.

Concurrent Chemo, Immunotherapy Offers Viable Option in Metastatic Bladder Cancer

April 21st 2018

In particular, patients whose tumors have certain genetic mutations may respond especially well to this combination approach.

There Are Multiple Dynamic Biomarkers for Bladder Cancer

April 20th 2018

While there are a few common and well-known checkpoints for bladder cancer, there are also many more than PD-1, PD-L1 and CTLA-4.

Chemotherapy Could Make a Comeback, But Only Clinical Trials Will Tell

March 23rd 2018

Chemotherapy can aid in making a tumor “hot” – meaning that it attracts tumor-infiltrating lymphocytes (TILs), which are linked to killing tumor cells – priming it to respond better to immunotherapy treatment.

Patient Education Key in Flexible Dosing Schedule for Opdivo

March 22nd 2018

After a recent FDA approval for an additional dosing schedule option for Opdivo, patients must be educated on the potential side effects that may occur between prolonged visits.

Patients Now Have the Option to Undergo Immunotherapy Less Frequently

March 6th 2018

The Food and Drug Administration (FDA) has approved a supplemental biologics license application adding a four-week dosing schedule for Opdivo (nivolumab) across several of the PD-1 inhibitor’s indications.

Efficacy Offsets High Costs for Immunotherapy in US, But Not Overseas

February 14th 2018

Researchers from Israel, the United Kingdom (UK) and Canada sought to determine the cost-effectiveness of Keytruda for the second-line treatment of patients with advanced bladder cancer. Drug costs were compared between the US, UK, Canada and Australia.

Dietary Intervention Helps Pre-Diabetic Patients With Bladder Cancer

February 10th 2018

Patients with diabetes are at a greater risk for bladder cancer, and worse, for disease recurrence and progression. So, recent research investigated if a certain diet would help.

Managing Toxicity Amidst Immunotherapy Expansion in Bladder Cancer Is Critical

February 5th 2018

Now that a number of immunotherapy agents have been approved in the bladder cancer space, identifying and managing the toxicities that may come along with them is critical.

The Future of Bladder Cancer Treatment

January 25th 2018

Daniel J. George, M.D., discusses the role of immunotherapy, its continued integration into standards of care and what else the future holds for the treatment of bladder cancer.

Inner-Ear Buildup of Cisplatin May Cause Hearing Loss

January 5th 2018

“As the population of cancer survivors continues to grow, so does the importance of addressing the long-term sequelae of cancer treatment,” the authors wrote. “This hearing loss can result in multifaceted decrease in quality of life, and in pediatric patients it can impact social and academic development.”

Combination Immunotherapy Shows Promise for Bladder Cancer

December 26th 2017

When combined with other regimens in the treatment of patients with bladder cancer, immunotherapy has been shown to be beneficial, according to Arjun Balar, M.D.

Immunotherapy Combinations Are Being Explored in Bladder Cancer

December 13th 2017

To take the next step in this research, investigators are now combining immunotherapies together, or with chemotherapy, to create added benefits and more durable, long-lasting responses.

2017 Was the Year of Immunotherapy for Bladder Cancer

December 13th 2017

There were monumental advances in the treatment of bladder cancer during the year 2017, with five approvals for checkpoint inhibitors in both the first and second line setting